Cited by 226Alzheimer's disease research and treatmentsAutophagy in Disease and TherapyNeuroinflammation and Neurodegeneration Mechanisms

Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice.

Open access
Ozcelik, Sefika, Fraser, Graham, Castets, Perrine, Schaeffer, Véronique, Skachokova, Zhiva, Breu, Karin, Clavaguera, Florence, Sinnreich, Michael +4 more·2013·PLoS ONE

Abstract

Altered autophagy contributes to the pathogenesis of Alzheimer's disease and other tauopathies, for which curative treatment options are still lacking. We have recently shown that trehalose reduces tau pathology in a tauopathy mouse model by stimulation of autophagy. Here, we studied the effect of the autophagy inducing drug rapamycin on the progression of tau pathology in P301S mutant tau transgenic mice. Rapamycin treatment resulted in a significant reduction in cortical tau tangles, less tau hyperphosphorylation, and lowered levels of insoluble tau in the forebrain. The favourable effect of rapamycin on tau pathology was paralleled by a qualitative reduction in astrogliosis. These effects were visible with early preventive or late treatment. We further noted an accumulation of the autophagy associated proteins p62 and LC3 in aged tangle bearing P301S mice that was lowered upon rapamycin treatment. Thus, rapamycin treatment defers the progression of tau pathology in a tauopathy animal model and autophagy stimulation may constitute a therapeutic approach for patients suffering from tauopathies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0062459

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Rapamycin treatment inhibits both tau hyperphosphorylation and the development of status epilepticus and chronic epilepsy in models of pharmacological seizure induction, temporal lobe epilepsy, and post-traumatic epilepsy.

    “Rapamycin treatment inhibits both tau hyperphosphorylation (Liu et al., 2013; Ozcelik et al., 2013; Tramutola et al., 2017) and the development of status epilepticus and chronic epilepsy in models of pharmacological seizure induction (Zeng et al., 2008; Huang et al., 2010), TLE (Drion et al., 2016), and PTE (Guo et al., 2013; Butler et al., 2015).”

    From Tauopathy and Epilepsy Comorbidities and Underlying Mechanisms (2022) · cites this paper as Ozcelik et al., 2013

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ozcelik, S., Fraser, G., Castets, P., Schaeffer, V., Skachokova, Z., Breu, K., Clavaguera, F., Sinnreich, M., Kappos, L., Goedert, M., Tolnay, M., & Winkler, D. T.
Affiliations
  • MRC Laboratory of Molecular Biology (GB)
  • University Hospital of Basel (CH)
Corresponding author
Winkler, David Theo
Venue
PLoS ONE
Published
2013-05-07
Volume
8
Issue
5
Pages
e62459
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1989723790
Cited by
226
References
38
Citations by year
2026: 7 · 2025: 16 · 2024: 9 · 2023: 15 · 2022: 27 · 2021: 26 · 2020: 31 · 2019: 17 · 2018: 17 · 2017: 17 · 2016: 18 · 2015: 17 · 2014: 7 · 2013: 2
FWCI
10.42
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Science Foundation
  • University of Pennsylvania
  • Velux Stiftung
  • Parkinson's UK (K-1012)
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (135214, 123812, 310030)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
rapamycin, tau pathology, P301S tau transgenic mice, tauopathy, Alzheimer's disease, autophagy, tau hyperphosphorylation, tau tangles, astrocyte activation, p62, LC3, trehalose, neuroprotection
MeSH terms
Animals, Astrocytes, Humans, Mice, Transgenic, Phosphorylation, Solubility, Time Factors, tau Proteins, Disease Progression, Sirolimus, Tauopathies, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review